Publication | Open Access
Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children
35
Citations
94
References
2024
Year
ImmunodeficienciesImmunologyPediatric Lung DiseaseImmunodominanceAuto-abs Neutralizing 100Auto-abs Neutralizing Ifn-ωImmunotherapyAutoimmune Liver DiseaseCovid-19Clinical EpidemiologyRespiratory InfectionAutoantibodiesInfection ControlPublic HealthCovid-19 PneumoniaAutoimmune DiseaseAutoimmunityImmunologic DiseaseClinical Infectious DiseaseEpidemiologyAnti-ifn-ω Auto-absAntiviral TherapyInfectious Respiratory DiseaseMedicineViral Immunity
We found that 19 (10.4%) of 183 unvaccinated children hospitalized for COVID-19 pneumonia had autoantibodies (auto-Abs) neutralizing type I IFNs (IFN-α2 in 10 patients: IFN-α2 only in three, IFN-α2 plus IFN-ω in five, and IFN-α2, IFN-ω plus IFN-β in two; IFN-ω only in nine patients). Seven children (3.8%) had Abs neutralizing at least 10 ng/ml of one IFN, whereas the other 12 (6.6%) had Abs neutralizing only 100 pg/ml. The auto-Abs neutralized both unglycosylated and glycosylated IFNs. We also detected auto-Abs neutralizing 100 pg/ml IFN-α2 in 4 of 2,267 uninfected children (0.2%) and auto-Abs neutralizing IFN-ω in 45 children (2%). The odds ratios (ORs) for life-threatening COVID-19 pneumonia were, therefore, higher for auto-Abs neutralizing IFN-α2 only (OR [95% CI] = 67.6 [5.7-9,196.6]) than for auto-Abs neutralizing IFN-ω only (OR [95% CI] = 2.6 [1.2-5.3]). ORs were also higher for auto-Abs neutralizing high concentrations (OR [95% CI] = 12.9 [4.6-35.9]) than for those neutralizing low concentrations (OR [95% CI] = 5.5 [3.1-9.6]) of IFN-ω and/or IFN-α2.
| Year | Citations | |
|---|---|---|
Page 1
Page 1